Cross-clade T lymphocyte-mediated immunity to HIV type 1: Implications for vaccine design and immunodetection assays

AIDS Research and Human Retroviruses

Volumn 18, Issue 14, 2002, Pages 1067-1079

  Keating, Sheila M ^a   Bollinger, Robert C ^a   Quinn, Thomas C ^a   Jackson, J Brooks ^a   Carruth, Lucy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CELLULAR IMMUNITY; CLADISTICS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNODETECTION; INTERFERON PRODUCTION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SCREENING; SERODIAGNOSIS; T LYMPHOCYTE;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 0036392217     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220260235425     Document Type: Article

References (36)

1. UNAIDS: Report on the Global AIDS Epidemic. 6-27-2000. Ref Type: Internet Communication
2. Mascola JR and Nabel GJ: Vaccines for the prevention of HIV-1 disease. Curr Opin Immunol 2001;13:489-495.
3. Mooij P and Heeney JL: Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine 2001;20:304-321.
4. Barouch DH and Letvin NL: CD81 cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr Opin Immunol 2001;13:479-482.
5. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
6. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655.
7. Rowland-Jones S, Dong T, Krausa P, et al.: The role of cytotoxic T-cells in HIV infection. Dev Biol Stand 1998;92:209-214.
8. Cao H, Kanki P, Sankale JL, et al.: Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J Virol 1997;71: 8615-8623.
9. Gotch F: Cross-clade T cell recognition of HIV.1. Curr Opin Immunol 1998;10:388-392.
10. Carr JK, Torimiro JN, Wolfe ND, et al.: The AG recombinant IbNG and novel strains of group M HIV-1 are common in Cameroon. Virology 2001;286:168-181.
11. Tovanabutra S, Polonis V, De Souza M, et al.: First CRF01_AE/B recombinant of HIV-1 is found in Thailand. AIDS 2001;15: 1063-1065.
12. Yu XF, Liu W, Chen J, et al.: Rapid dissemination of a novel B/C recombinant HIV-1 among injection drug users in southern China. AIDS 2001;15:523-525.
13. Altfeld M, Addo MM, Eldridge RL, et al.: Vpr is preferentially targeted by CTL during HIV-1 infection. J Immunol 2001;167: 2743-2752.
14. Dorrell L, Willcox BE, Jones EY, et al.: Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 Gag through HLA-B53. Eur J Immunol 2001;31:1747-1756.
15. Novitsky V, Rybak N, McLane MF, et al.: Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific ELISpot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 2001;75:9210 -9228.
16. Schmechel SC, Russell N, Hladik F, et al.: Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons. Immunol Lett 2001;79:21-27.
17. Betts MR, Casazza JP, Patterson BA, et al.: Putative immunodominant human immunodeficiency virus-specific CD81 T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol 2000;74:9144-9151.
18. +-T-cell response to human cytomegalovirus: The 72-kilodalton major immediate-early protein revisited. J Virol 1999;73:8179-8184.
19. Tobery TW, Wang S, Wang XM, et al.: A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. J Immunol Methods 2001;254:59-66.
20. Whiteside TL: Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin Diagn Lab Immunol 2000;7:327-332.
21. Currier J, Kuta E, Turk E, et al.: A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assay. J Immunol Methods 2002.
22. Anonymous: HIV subtypes: Implications for epidemiology, pathogenesis, vaccines and diagnostics. AIDS 1997;11:17-36.
23. Goulder PJ, Brander C, Annamalai K, et al.: Differential narrow focusing of immunodominant human immunodeficiency virus Gag-specific cytotoxic T-lymphocyte responses in infected African and Caucasoid adults and children. J Virol 2000;74:5679-5690.
24. Korber B, Brander C, Haynes BF, Moore JP, Koup RA, Kuiken C, Walker BD, and Watkins DI: HIV Molecular Immunology Data Base. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 2000.
25. Wagner R, Leschonsky B, Harrer E, et al.: Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: Constraints on immune escape associated with targeting a sequence essential for viral replication. J Immunol 1999;162:3727-3734.
26. Goepfert PA, Bansal A, Edwards BH, et al.: A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce γ interferon. J Virol 2000;74:10249-10255.
27. + T cells. Immunol Lett 2001;79:141-150.
28. + T cell epitopes from complex antigens. J Immunol 2001;166: 6665-6670.
29. Maecker HT, Dunn HS, Suni MA, et al.: Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001;255:27-40.
30. Huang XL, Fan Z, Kalinyak C, et al.: CD81 T-cell γ interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects. Clin Diagn Lab Immunol 2000;7:279-287.
31. Larsson M, Jin X, Ramratnam B, et al.: A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 1999;13: 767-777.
32. Shacklett BL, Cu-Uvin S, Beadle TJ, et al.: Quantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface. AIDS 2000;14:1911-1915.
33. Evans TG, Kallas EG, Campbell M, et al.: Evaluation of canary-pox-induced CD81 responses following immunization by measuring the effector population IFNγ production. Immunol Lett 2001;77:7-15.
34. Brander C, Hartman KE, Trocha AK, et al.: Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodefi-ciency virus-1 infection. J Clin Invest 1998;101:2559-2566.
35. Day CL, Shea AK, Altfeld MA, et al.: Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J Virol 2001;75:6279-6291.
36. Addo MM, Altfeld M, Rosenberg ES, et al.: The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001;98:1781-1786.